Axsome Therapeutics Inc (AXSM)

Axsome Therapeutics (AXSM) Financial Statements


Axsome Therapeutics Financial Overview

Axsome Therapeutics's market cap is currently ―. The company's EPS TTM is $-6.384; its P/E ratio is -13.12; Axsome Therapeutics is scheduled to report earnings on August 5, 2024, and the estimated EPS forecast is $-1.30. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Sep 23Jun 23Mar 23
Income Statement-
Total Revenue$ 75.00M$ 71.53M$ 57.79M$ 46.02M$ 94.58M
Gross Profit$ 68.70M$ 107.36M$ 51.08M$ 48.15M$ 94.74M
EBIT$ -69.73M$ -94.05M$ -57.99M$ -63.72M$ -12.27M
EBITDA$ -67.27M$ -91.83M$ -55.62M$ -61.44M$ -9.71M
Net Income Common Stockholders$ -68.36M$ -98.65M$ -62.56M$ -67.17M$ -11.22M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 331.44M$ 386.19M$ 416.56M$ 437.11M$ 246.51M
Total Assets$ 545.73M$ 588.24M$ 600.86M$ 611.64M$ 388.48M
Total Debt$ 188.80M$ 186.37M$ 185.57M$ 184.71M$ 147.72M
Net Debt$ -142.64M$ -199.82M$ -230.99M$ -252.40M$ -98.79M
Total Liabilities$ 401.69M$ 397.26M$ 331.35M$ 332.83M$ 277.37M
Stockholders Equity$ 144.04M$ 190.98M$ 269.51M$ 278.82M$ 111.76M
Cash Flow-
Free Cash Flow$ -53.56M$ -30.37M$ -53.92M$ -55.48M$ -5.89M
Operating Cash Flow$ -53.47M$ -30.36M$ -53.55M$ -55.35M$ -5.82M
Investing Cash Flow$ -98.00K$ -7.00K$ -371.00K$ -133.00K$ -71.00K
Financing Cash Flow$ -1.19M$ -2.00K$ 33.37M$ 246.08M$ 51.56M
Currency in USD

Axsome Therapeutics Earnings and Revenue History

Axsome Therapeutics Debt to Assets

Axsome Therapeutics Cash Flow

Axsome Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis